LGL Group (NYSEAMERICAN:LGL) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

LGL Group, Inc. (The) (NYSEAMERICAN:LGL)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.45 and traded as high as $7.15. LGL Group shares last traded at $7.05, with a volume of 9,613 shares trading hands.

LGL Group Trading Down 1.5%

The firm has a market capitalization of $38.99 million, a PE ratio of 41.47 and a beta of 0.31. The business’s 50 day simple moving average is $6.96 and its 200 day simple moving average is $6.45.

Insider Buying and Selling at LGL Group

In related news, major shareholder Mario J. Gabelli purchased 95,387 shares of the firm’s stock in a transaction that occurred on Tuesday, December 30th. The shares were bought at an average price of $4.75 per share, for a total transaction of $453,088.25. Following the acquisition, the insider owned 572,324 shares of the company’s stock, valued at approximately $2,718,539. This represents a 20.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC purchased a new position in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.